SU24.2-3 | Pancreatic Endocrine Tumours — Summary & Reflection

KEY TAKEAWAYS

Pancreatic endocrine tumours (PNETs) arise from islet cells and are functioning (a hormone-driven syndrome) or non-functioning (mass/metastasis, late presentation). The key functioning types are: insulinoma (insulin → fasting hypoglycaemia, Whipple's triad; commonest, usually benign), gastrinoma (gastrin → Zollinger-Ellison syndrome: refractory/atypical peptic ulcers + diarrhoea; often malignant), and the rarer VIPoma (watery diarrhoea/WDHA), glucagonoma (necrolytic migratory erythema, diabetes) and somatostatinoma. Watch for MEN-1 — the 3 Ps: Parathyroid, Pituitary, Pancreatic. Investigation is confirm-first, localise-second: insulinoma via a supervised 72-hour fast (hypoglycaemia with inappropriately raised insulin AND C-peptide — C-peptide proves endogenous insulin); gastrinoma via raised fasting gastrin with high acid output; then localise with CT/MRI, endoscopic ultrasound and somatostatin-receptor imaging (Ga-68 DOTATATE), and screen for MEN-1. Management: surgical resection/enucleation cures localised benign insulinoma; high-dose PPIs then resection for gastrinoma; somatostatin analogues for metastatic disease. Prognosis is good for benign insulinoma and varies with malignancy and metastasis for the rest — all within the same disciplined framework that governs pancreatic disorders overall.

REFLECT

Imagine you are the clinician who finally recognises that a patient's repeated 'funny turns', always relieved by food, are not anxiety or epilepsy but an insulinoma. How would you explain to them why the next step is a carefully supervised fast rather than an immediate scan — and why measuring C-peptide as well as insulin matters? Now reflect on the gastrinoma patient whose ulcers never healed: how does naming the hormone change the treatment from yet another course of ulcer therapy to high-dose acid suppression and a hunt for a tumour? Finally, consider the thread that runs through this whole cluster — adrenal disorders, adrenal tumours, pancreatitis and now endocrine pancreatic tumours: in every one, you confirm the diagnosis biochemically or pathologically first, localise or define it second, and treat last. Reflect on how that single discipline, more than any individual fact, is what makes endocrine and pancreatic surgery safe.